search icon
lyra-img

Lyra Therapeutics Inc, Common Stock

LYRA

NAQ

$0.157

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$10.75M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
65.47K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.18
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.14 L
$6.68 H
$0.157

About Lyra Therapeutics Inc, Common Stock

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLYRASectorS&P500
1-Week Return-2.01%-1.07%2.86%
1-Month Return-23.37%-2.43%-2.88%
3-Month Return-13.4%4.06%-4.01%
6-Month Return-41.95%-4.8%0.96%
1-Year Return-97.46%0.02%11.03%
3-Year Return-96.6%6.6%27.52%
5-Year Return-99.16%78.38%134.16%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-285.00K1.36M1.56M1.53M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":18.29,"profit":true},{"date":"2022-12-31","value":87.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":98.46,"profit":true}]
Cost of Revenue95.00K1.00M1.07M48.03M-[{"date":"2020-12-31","value":0.2,"profit":true},{"date":"2021-12-31","value":2.08,"profit":true},{"date":"2022-12-31","value":2.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(95.00K)285.00K296.00K1.56M1.53M[{"date":"2020-12-31","value":-6.1,"profit":false},{"date":"2021-12-31","value":18.29,"profit":true},{"date":"2022-12-31","value":19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":98.46,"profit":true}]
Gross Margin-100.00%21.72%100.00%100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":21.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses22.21M43.90M56.35M68.68M97.88M[{"date":"2020-12-31","value":22.69,"profit":true},{"date":"2021-12-31","value":44.85,"profit":true},{"date":"2022-12-31","value":57.57,"profit":true},{"date":"2023-12-31","value":70.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(22.21M)(43.62M)(56.31M)(67.12M)(96.35M)[{"date":"2020-12-31","value":-2220900000,"profit":false},{"date":"2021-12-31","value":-4361500000,"profit":false},{"date":"2022-12-31","value":-5630600000,"profit":false},{"date":"2023-12-31","value":-6712000000,"profit":false},{"date":"2024-12-31","value":-9634800000,"profit":false}]
Total Non-Operating Income/Expense164.00K204.00K2.08M8.59M5.90M[{"date":"2020-12-31","value":1.91,"profit":true},{"date":"2021-12-31","value":2.37,"profit":true},{"date":"2022-12-31","value":24.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":68.71,"profit":true}]
Pre-Tax Income(22.13M)(43.51M)(55.27M)(62.62M)(93.40M)[{"date":"2020-12-31","value":-2212700000,"profit":false},{"date":"2021-12-31","value":-4351300000,"profit":false},{"date":"2022-12-31","value":-5526500000,"profit":false},{"date":"2023-12-31","value":-6262100000,"profit":false},{"date":"2024-12-31","value":-9339600000,"profit":false}]
Income Taxes(82.00K)(1.10M)13.00K59.00K39.00K[{"date":"2020-12-31","value":-138.98,"profit":false},{"date":"2021-12-31","value":-1869.49,"profit":false},{"date":"2022-12-31","value":22.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":66.1,"profit":true}]
Income After Taxes(22.05M)(42.41M)(55.28M)(62.68M)(93.44M)[{"date":"2020-12-31","value":-2204500000,"profit":false},{"date":"2021-12-31","value":-4241000000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6268000000,"profit":false},{"date":"2024-12-31","value":-9343500000,"profit":false}]
Income From Continuous Operations(22.13M)(43.51M)(55.28M)(61.76M)(93.44M)[{"date":"2020-12-31","value":-2212700000,"profit":false},{"date":"2021-12-31","value":-4351300000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6175900000,"profit":false},{"date":"2024-12-31","value":-9343500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(22.05M)(42.41M)(55.28M)(62.68M)(93.44M)[{"date":"2020-12-31","value":-2204500000,"profit":false},{"date":"2021-12-31","value":-4241000000,"profit":false},{"date":"2022-12-31","value":-5527800000,"profit":false},{"date":"2023-12-31","value":-6268000000,"profit":false},{"date":"2024-12-31","value":-9343500000,"profit":false}]
EPS (Diluted)(20.21)(3.35)(1.75)(1.25)(1.37)[{"date":"2020-12-31","value":-2021,"profit":false},{"date":"2021-12-31","value":-335,"profit":false},{"date":"2022-12-31","value":-175,"profit":false},{"date":"2023-12-31","value":-125,"profit":false},{"date":"2024-12-31","value":-137.04,"profit":false}]

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top